Jiangxi Institute of Biological Products Inc.(06915.HK): Subsidiary Obtains Approval Number for Veterinary Tetanus Antitoxin

NewTimeSpace News: On July 3, 2026, Jiangxi Institute of Biological Products Inc.(06915.HK) issued an announcement, stating that its wholly-owned subsidiary Chifeng Boen Pharmaceutical has successfully secured the approval number certificate for veterinary tetanus antitoxin.

This product is mainly applied for the prevention and treatment of tetanus infection in animals, providing passive immune protection for animals by neutralizing tetanus toxin. The company commented that this approval further diversifies its product portfolio, helping strengthen overall competitiveness and long-term growth potential.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.